Patents Examined by Layla D Berry
  • Patent number: 11117916
    Abstract: The present invention relates a process for the recovery of one or more steviol glycosides from a steviol glycoside-containing fermentation broth, which method comprises (a) providing a fermentation broth comprising one or more steviol glycosides and one or more non-steviol glycoside components; (b) separating the liquid phase of the broth from the solid phase of the broth; (c) providing an adsorbent resin; (d) contacting the liquid phase of the broth with the adsorbent resin in order to separate at least a portion of the one or more steviol glycosides from the non-steviol glycoside components, thereby to recover one or more steviol glycosides from the fermentation broth containing one or more steviol glycosides. The invention also relates to a purified steviol glycoside composition prepared using such a process.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: September 14, 2021
    Assignee: DSM IP ASSETS B.V.
    Inventor: Igor Galaev
  • Patent number: 11111263
    Abstract: The present invention relates to a process for manufacturing (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid with the formula (Id) below and salts thereof The compound of formula (Id) is a prodrug of a catecholamine for use in treatment of neurodegenerative diseases and disorders such as Parkinson's Disease. The invention also relates to new intermediates of said process.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: September 7, 2021
    Assignee: H. Lundbeck A/S
    Inventors: Martin Juhl, Frans Dennis Therkelsen, Tobias Gylling Frihed
  • Patent number: 11110116
    Abstract: The invention relates to a novel hyperosmolar composition of hyaluronic acid for the use thereof in the treatment of conical oedema.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: September 7, 2021
    Assignee: Horus Pharma
    Inventors: Jean-François Rouland, Martine Claret, Claude Claret
  • Patent number: 11111317
    Abstract: A Cordyceps militaris medium polysaccharide, a method for separating and purifying same, and the use thereof, wherein the polysaccharide comprises the following monosaccharides in mole percentages: 0.11% ribose, 0.11% rhamnose, 0.45% arabinose, 0.13% xylose, 14.50% mannose, 83.96% glucose, and 0.73% galactose. The extraction method does not affect the biological activity of the Cordyceps militaris medium polysaccharide P1; the obtained purified polysaccharide P1 has high purity and stable properties, and has significant effects on resistance to oxidation, lowering uric acid and bacteriostasis, which are beneficial to human metabolism; due to the low cost, the purified polysaccharide P1 can be further used in the development of health products, drugs and cosmetics.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: September 7, 2021
    Assignee: SOUTH CHINA NORMAL UNIVERSITY
    Inventors: Ruqiang Huang, Jingwen Zhang, Jinghui Wang, Qian Wang, Linlin Gao
  • Patent number: 11111264
    Abstract: The present disclosure relates to crystalline morphic forms of 4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide. The morphic form can be a stable hemihydrate crystalline form.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: September 7, 2021
    Assignee: Chimerix, Inc.
    Inventors: Roy W. Ware, Venkat Lakshmanan, Aaron Leigh Downey
  • Patent number: 11103526
    Abstract: PNPase inhibitors (such as 8-substituted guanine and/or 8-substituted guanosine) and/or PNPase purine nucleoside substrates (such as guanosine and/or inosine) can also be used in methods of treating SCD or reducing sickling of red blood cells (RBCs). Herein, 8-substituted guanine and/or 8-substituted guanosine compounds are used in methods to treat hypertension (such as systemic or pulmonary hypertension), stroke, diabetes, and/or patients in need of a diuretic. In addition, 8-substituted guanine and/or 8-substituted guanosine compounds are included in a beverage composition. Further, purine nucleoside phosphorylase (PNPase) inhibitors (such as 8-substituted guanine and/or 8-substituted guanosine) and/or PNPase purine nucleoside substrates (such as guanosine and/or inosine) can be used in methods of treating or reducing the risk of pulmonary hypertension (PH), such as PH associated with HIV or sickle cell disease (SCD).
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: August 31, 2021
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Edwin K. Jackson, Stevan P. Tofovic
  • Patent number: 11104746
    Abstract: This invention relates to an improved process for the synthesis of Sugammadex or a salt thereof, to Sugammadex or a salt thereof having high purity as obtained by said process and to pharmaceutical compositions comprising said high purity Sugammadex or a salt thereof.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: August 31, 2021
    Assignee: Medichem, S.A.
    Inventors: Jordi Puig Serrano, Jordi Bosch I Llado, Iteng Ng Choi, Ernesto Duran López
  • Patent number: 11097008
    Abstract: The present invention is directed colloidal microcrystalline compositions, particularly for suspending particles in low viscosity fluids, produced by co-attrition of a mixture of microcrystalline cellulose and at least a polysaccharide in the presence of acidic attrition aid; their preparation; and, products made therewith.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: August 24, 2021
    Assignee: DUPONT NUTRITION USA, INC.
    Inventors: Hong Yang, Jeremy Ondov, Toh Mei Yan Joyce, Aaron Chip Venables, Simon Eustace, Kevin Stokes
  • Patent number: 11098135
    Abstract: The invention relates to a novel methylated cyclodextrin and to a novel method used for the production thereof. The invention also relates to the use of said methylated cyclodextrin for the solubilisation of lipophilic compounds, or carriers of at least one lipophilic group. The invention further relates to a composition comprising said methylated cyclodextrin, particularly a pharmaceutical composition.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: August 24, 2021
    Inventors: Xavier Parissaux, Jean-Baptiste Palmieri, Mathias Ibert, Clothilde Buffe
  • Patent number: 11091510
    Abstract: The present invention provides the preparation processes for several crystal forms of the compound 17beta-Neriifolin (17bNF) and use thereof in anti-tumor applications. The present invention provides preparation processes for four kinds of non-solvated crystal forms, amorphous powders and eleven kinds of solvated crystalline solids, including ethanol-solvated ones, of 17bNF that are not present in nature, and the identification and characterization of these crystal forms by crystallographic research methods such as X-ray powder diffraction. In addition, through vivo anti-tumor experiments with five of the crystal forms in nude mice, we provide anti-tumor and anti-cancer applications of the crystal forms of 17bNF.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: August 17, 2021
    Assignees: ENKANG PHARMACEUTICALS (GUANGZHOU), LTD., ENZHI (GUANGZHOU) PHARMACEUTICALS LIMITED, ENZYNOMICS (H.K.) LIMITED, FOSHAN INTELGEN PHARMACEUTICAL CO. LTD.
    Inventors: Chun Liang, Haibin Liu, Zeming Zhang, Guoqiang Song, Yushan Li, Weiqiang Zhang
  • Patent number: 11090324
    Abstract: The present disclosure relates to a composition for preventing, treating or remedying female climacteric syndrome symptoms, which contains tectorigenin 7-O-xylosylglucoside. The composition according to the present disclosure shows quick effects for preventing, remedying and/or treating female climacteric syndrome symptoms, particularly facial flushing and/or osteoporosis, and thus can be utilized for the hormone replacement therapy (HRT) used for preventing or remedying climacteric syndrome symptoms.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: August 17, 2021
    Inventors: Bo-Young Lee, Ho-Song Cho, Soon-Ran Song, Won-Kyung Lee, Chang-Il Choi, Sang-Hwa Lee
  • Patent number: 11084841
    Abstract: The present invention provides a chitooligosaccharide-N-geraniol derivative and a preparation method and application thereof. The degree of substitution of a chitooligosaccharide-N-geraniol derivative is from 0.26 to 0.283. The method includes dissolving oligosaccharide in dimethyl sulfoxide, dissolving geranyl bromide in dimethylformamide, and then mixing, performing a water bath reaction and adding acetone in after the water bath reaction, performing a centrifugation and collecting precipitates, performing Soxhlet extraction and vacuum drying to obtain the chitooligosaccharide-N-geraniol derivative. The present invention has the advantages of easy preparation method, low cost, simple purification method and stable properties. The chitooligosaccharide derivative has good water solubility, antibacterial activity against Staphylococcus aureus, Escherichia coli and other bacteria, and has good application prospect in the fields of medicine, food, cosmetics, agriculture, etc.
    Type: Grant
    Filed: September 15, 2020
    Date of Patent: August 10, 2021
    Assignee: Jiangnan University
    Inventors: Lin Yue, Ran Bi, Dan Sun, Qixing Jiang, Bin Wang, Xiaoli Liu, Peipei Yu, Zhouping Wang, Wenshui Xia
  • Patent number: 11084888
    Abstract: The present invention provides a production method for pseudo-polyrotaxane or polyrotaxane in which the degree of ring-shaped molecules included on straight-chain molecules, that is, the inclusion rate, has been controlled to be low and stable.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: August 10, 2021
    Assignee: ASM, Inc.
    Inventor: Katsunari Inoue
  • Patent number: 11084840
    Abstract: The present invention relates to a method of purifying allulose and a method of preparing allulose using the method of purifying, and more specifically the purification method includes mixing allulose conversion product with powdered activated carbon and applying the solid-liquid separation to efficiently remove impurities.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: August 10, 2021
    Assignee: SAMYANG CORPORATION
    Inventors: Kyung-Hun Ryu, Hye Jung Kim, Sung Won Park, Chong Jin Park
  • Patent number: 11077129
    Abstract: The invention relates to compositions of nicotinoyl ribosides and nicotinamide riboside derivatives and their methods of use. In some embodiments, the invention relates to methods of making nicotinoyl ribosides. In some embodiments, the invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinoyl riboside. In further embodiments, the invention relates to methods of using nicotinoyl ribosides and nicotinamide riboside derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for improving cell and tissue survival.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: August 3, 2021
    Assignee: Cornell University
    Inventors: Anthony A. Sauve, Tianle Yang Redanz
  • Patent number: 11072667
    Abstract: The present invention provides a polyrotaxane having high durability and in particular, high hydrolysis resistance, and a method for producing said polyrotaxane. The present invention provides a polyrotaxane obtained by disposing blocking groups on both ends of a pseudopolyrotaxane so that an annular molecule cannot be displaced, said pseudopolyrotaxane being obtained by forming a clathrate by piercing the opening of the cyclic molecule with a linear molecule, said polyrotaxane being characterized in that the cyclic molecule has a substituent represented by formula I (in formula I, R1 represents a group such as —CH3 and —CH2—CH3, R2 represents H or a group such as —CH3, and n is the apparent degree of polymerization of a polyalkylene oxide chain or a derivative thereof added to the cyclic molecule, the value of n being 1.1 to 10.0).
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: July 27, 2021
    Assignee: ASM INC.
    Inventors: Katsunari Inoue, Masabumi Kudoh
  • Patent number: 11072626
    Abstract: The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: July 27, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Prasada Rao Jalagam, Satheesh Kesavan Nair, Manoranjan Panda, Alicia Regueiro-Ren
  • Patent number: 11072628
    Abstract: The present invention relates to novel nucleoside analogues and compositions containing said nucleoside analogues. Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the diagnosis, prevention and/or treatment of parasitic infections, more specifically for use in the diagnosis, prevention and/or treatment of a Trypanosoma infection.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: July 27, 2021
    Assignees: Universiteit Gent, Universiteit Antwerpen
    Inventors: Fabian Hulpia, Serge Van Calenbergh, Guy Caljon, Louis Maes
  • Patent number: 11071750
    Abstract: Disclosed are adducts of boric acid and chitosan wherein the amino groups of the D-glucosamine units are bonded to residues of polyol or alditol oligosaccharides, the molar ratio between boric acid and the repeating chitosan unit ranging between 0.001 and 4.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: July 27, 2021
    Assignees: BIOPOLIFE SRL, UNIVERSITA' DEGLI STUDI DI TRIESTE
    Inventors: Marco Bosco, Massimiliano Borgogna, Andrea Travan, Ivan Donati
  • Patent number: 11059851
    Abstract: The present invention relates to a process for the purification of methylcobalamin, namely from iron cyanide impurities, comprising contacting a solution comprising methylcobalamin and iron cyanide anions with a strongly basic anion exchange resin. This purification process can advantageously be used for removing iron cyanide impurities from methylcobalamin obtained by reductive methylation of cyanocobalamin and wherein iron (II) salts are used as cyanide scavengers, thus providing methylcobalamin with a reduced iron content. Methylcobalamin (R is methyl).
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: July 13, 2021
    Assignee: HEALTHTECH BIO ACTIVES, S.L.U.
    Inventors: Juan Sallares Rosell, Francisco Marquillas Olondriz